Matrix metalloproteinase inhibitors: a patent review (2011 – 2013)

Bibliography

• Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4
   PubMed Web of Science ®Google Scholar
• Norman P. Selective MMP-12 inhibitors: WO-2008057254. Expert Opin Ther Pat 2009;19:1029-34
   PubMed Web of Science ®Google Scholar
• Li NG, Shi ZH, Tang YP, et al. Selective matrix metallo proteinase inhibitors for cancer. Curr Med Chem 2009;16:3805-27
   PubMed Web of Science ®Google Scholar
• Winum JY, Scozzafava A, Montero JL, et al. The sulfamide motif in the design of enzyme inhibitors. Expert Opin Ther Pat 2006;16:27-47
   PubMed Web of Science ®Google Scholar
• Itoh Y. Metalloproteinase binding proteins: WO2009097397. Expert Opin Ther Pat 2010;20:1091-5
   PubMed Web of Science ®Google Scholar
• Palei AC, Granger JP, Tanus-Santos JE. Matrix metalloproteinases as drug targets in preeclampsia. Curr Drug Targets 2013;14:325-34
   PubMed Web of Science ®Google Scholar
• Roomi MW, Monterrey JC, Kalinovsky T, et al. Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep 2009;21:1323-33
   PubMed Web of Science ®Google Scholar
• Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003;3:489-501
   PubMed Web of Science ®Google Scholar
• Wilson LJ, Wang B, Yang SM, et al. Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy. Bioorg Med Chem Lett 2011;21:6485-90
   PubMed Web of Science ®Google Scholar
• Shi ZH, Li NG, Shi QP, et al. Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors. Bioorg Med Chem Lett 2013;23:1206-11
   PubMed Web of Science ®Google Scholar
• Freskos JN, Asmelash B, Gaston KR, et al. Design and synthesis of MMP inhibitors with appended fluorescent tags for imaging and visualization of matrix metalloproteinase enzymes. Bioorg Med Chem Lett 2013;23:5566-70
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang J, Xu W, et al. Novel matrix metalloproteinase inhibitors derived from quinoxalinone scaffold (Part I). Bioorg Med Chem 2010;18:1516-25
   PubMed Web of Science ®Google Scholar
• Wang J, Medina C, Radomski MW, et al. N-substituted homopiperazine barbiturates as gelatinase inhibitors. Bioorg Med Chem 2011;19:4985-99
   PubMed Web of Science ®Google Scholar
• Topai A, Breccia P, Minissi F, et al. In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors. Bioorg Med Chem 2012;20:2323-37
   PubMed Web of Science ®Google Scholar
• Wang L, Li X, Zhang S, et al. Natural products as a gold mine for selective matrix metalloproteinases inhibitors. Bioorg Med Chem 2012;20:4164-71
   PubMed Web of Science ®Google Scholar
• Cheng XC, Wang RL, Dong ZK, et al. Design, synthesis and evaluation of novel metalloproteinase inhibitors based on L-tyrosine scaffold. Bioorg Med Chem 2012;20:5738-44
   PubMed Web of Science ®Google Scholar
• Tauro M, Laghezza A, Loiodice F, et al. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors. Bioorg Med Chem 2013;21:6456-65
   PubMed Web of Science ®Google Scholar
• Nuti E, Casalini F, Santamaria S, et al. Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. Eur J Med Chem 2011;46:2617-29
   PubMed Web of Science ®Google Scholar
• Wang J, O’Sullivan S, Harmon S, et al. Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion. J Med Chem 2012;55:2154-62
   PubMed Web of Science ®Google Scholar
• Reich R, Hoffman A, Veerendhar A, et al. Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment. J Med Chem 2012;55:7875-82
   PubMed Web of Science ®Google Scholar
• Gooyit M, Song W, Mahasenan KV, et al. O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier. J Med Chem 2013;56:8139-50
   PubMed Web of Science ®Google Scholar
• Li NG, Tang YP, Duan JA. New selective inhibitors of MMP-13 for inflammatory diseases: a patent evaluation (W02012151158). Expert Opin Ther Pat 2013;23:669-75
   PubMed Web of Science ®Google Scholar
• Iannone F, Lapadula G. The pathophysiology of osteoarthritis. Aging Clin Exp Res 2003;15:364-72
   PubMed Web of Science ®Google Scholar
• Johnson AR, Pavlovsky AG, Ortwine DF, et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasias side effects. J Biol Chem 2007;282:27781-91
   PubMed Web of Science ®Google Scholar
• Li NG, Shi ZH, Tang YP, et al. New hope for the treatment of osteoarthritis through selective inhibition of MMP-13. Curr Med Chem 2011;18:977-1001
   PubMed Web of Science ®Google Scholar
• Schnute ME, O’Brien PM, Nahra J, et al. Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg Med Chem Lett 2010;20:576-80
   PubMed Web of Science ®Google Scholar
• Kolodziej SA, Hockerman SL, Boehm TL, et al. Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates. Bioorg Med Chem Lett 2010;20:3557-60
   PubMedGoogle Scholar
• Kolodziej SA, Hockerman SL, DeCrescenzo GA, et al. MMP-13 selective isonipecotamide alpha-sulfone hydroxamates. Bioorg Med Chem Lett 2010;20:3561-4
   PubMed Web of Science ®Google Scholar
• Gao DA, Xiong Z, Heim-Riether A, et al. SAR studies of non-zinc-chelating MMP-13 inhibitors: improving selectivity and metabolic stability. Bioorg Med Chem Lett 2010;20:5039-43
   PubMed Web of Science ®Google Scholar
• Tommasi RA, Weiler S, McQuire LW, et al. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13. Bioorg Med Chem Lett 2011;21:6440-5
   PubMed Web of Science ®Google Scholar
• Roth J, Minond D, Darout E, et al. Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. Bioorg Med Chem Lett 2011;21:7180-4
   PubMed Web of Science ®Google Scholar
• La Pietra V, Marinelli L, Cosconati S, et al. Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization. Eur J Med Chem 2012;47:143-52
   PubMed Web of Science ®Google Scholar
• Taylor SJ, Abeywardane A, Liang S, et al. Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. J Med Chem 2011;54:8174-87
   PubMed Web of Science ®Google Scholar
• Gege C, Bao B, Bluhm H, et al. Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis. J Med Chem 2012;55:709-16
   PubMed Web of Science ®Google Scholar
• Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007;47:211-42
   PubMed Web of Science ®Google Scholar
• Ali MA, Fan X, Schulz R. Cardiac sarcomeric proteins: novel intracellular targets of matrix metalloproteinase-2 in heart disease. Trends Cardiovasc Med 2011;21:112-18
   PubMed Web of Science ®Google Scholar
• Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 2005;50:329-39
   PubMed Web of Science ®Google Scholar
• Gu Z, Cui J, Brown S, et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 2005;25:6401-8
   PubMed Web of Science ®Google Scholar
• Lorenzl S, Calingasan N, Yang L, et al. Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuromolecular Med 2004;5:119-32
   PubMedGoogle Scholar
• Lorenzl S, Albers DS, Relkin N, et al. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer’s disease. Neurochem Int 2003;43:191-6
   PubMedGoogle Scholar
• Jung SS, Zhang W, Van Nostrand WE. Pathogenic A beta induces the expression and activation of matrix metalloproteinase-2 in human cerebrovascular smooth muscle cells. J Neurochem 2003;85:1208-15
   PubMed Web of Science ®Google Scholar
• Opdenakker G, Nelissen I, Van Damme J. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol 2003;2:747-56
   PubMed Web of Science ®Google Scholar
• Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 2004;113:1447-55
   PubMed Web of Science ®Google Scholar
• Uzui H, Harpf A, Liu M, et al. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation 2002;106:3024-30
   PubMed Web of Science ®Google Scholar
• Antoniu SA. Matrix metalloproteinase inhibitors for chronic obstructive pulmonary disease. Drugs Future 2012;37:523-9
   Google Scholar
• Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002;115:3719-27
   PubMed Web of Science ®Google Scholar
• Valente P, Fassina G, Melchiori A, et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998;75:246-53
   PubMed Web of Science ®Google Scholar
• Guedez L, Courtemanch L, Stetler-Stevenson M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood 1998;92:1342-9
   PubMed Web of Science ®Google Scholar
• Bond M, Murphy G, Bennett MR, et al. Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J Biol Chem 2002;277:13787-95
   PubMed Web of Science ®Google Scholar
• Ahonen M, Poukkula M, Baker AH, et al. Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene 2003;22:2121-34
   PubMed Web of Science ®Google Scholar
• Jain P, Saravanan C, Singh SK. Sulphonamides: deserving class as MMP inhibitors? Eur J Med Chem 2013;60:89-100
   PubMed Web of Science ®Google Scholar
• Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003;22:177-203
   PubMed Web of Science ®Google Scholar
• Cheng XC, Wang Q, Fang H, et al. Role of sulfonamide group in matrix metalloproteinase inhibitors. Curr Med Chem 2008;15:368-73
   PubMedGoogle Scholar
• Jin Y, Roycik MD, Bosco DB, et al. Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core. J Med Chem 2013;56:4357-73
   PubMedGoogle Scholar
• Hugenberg V, Riemann B, Hermann S, et al. Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation. J Med Chem 2013;56:6858-70
   PubMed Web of Science ®Google Scholar
• Lovejoy B, Cleasby A, Hassell AM, et al. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. Science 1994;263:375-7
   PubMed Web of Science ®Google Scholar
• Gooley PR, O’Connell JF, Marcy AI, et al. The NMR structure of the inhibited catalytic domain of human stromelysin-1. Nat Struct Biol 1994;1:111-18
   PubMedGoogle Scholar
• Czarny B, Stura EA, Devel L, et al. Molecular determinants of a selective matrix metalloprotease-12 inhibitor: insights from crystallography and thermodynamic studies. J Med Chem 2013;56:1149-59
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gu Y, Lee HM, et al. Design, synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: a focus on chemically-modified curcumins. Curr Med Chem 2012;19:4348-58
   PubMed Web of Science ®Google Scholar
• Zhong HA, Arbiser J, Bowen JP. Selectivity, binding affinity, and ionization state of matrix metalloproteinase inhibitors. Curr Pharm Des 2013;19:4701-13
   PubMed Web of Science ®Google Scholar
• Shah PK, Wilkin DJ, Doherty TM, et al. Therapeutic developments in matrix metalloproteinase inhibition. Expert Opin Ther Pat 2002;12:665-707
   Web of Science ®Google Scholar
• Hu J, Van den Steen PE, Sang QX, et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007;6:480-98
   PubMed Web of Science ®Google Scholar
• Kawasaki Y, Xu ZZ, Wang X, et al. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med 2008;14:331-6
   PubMed Web of Science ®Google Scholar
• Tallahassee FL (US). Substituted heterocyclic mercaptosulfonamide metalloprotease inhibitors. US2011144179A1; 2011
   Google Scholar
• Jin UH, Lee JY, Kang SK, et al. A phenolic compound, 5-caffeoylquinic acid (chlorogenic acid), is a new type and strong matrix metalloproteinase-9 inhibitor: isolation and identification from methanol extract of Euonymus alatus. Life Sci 2005;77:2760-9
   PubMed Web of Science ®Google Scholar
• Institute of Botany in Jiangsu Province. New honeysuckle chlorogenic acid ester saponin as well as preparation method and use thereof. CN102050862A; 2011
   Google Scholar
• Glaxo Group Ltd. Matrix metalloproteinase inhibitors. AU2011202994A1; 2011
   Google Scholar
• Vernalis (Oxford) Ltd, Cambridge (GB); Laboratoires Serono S. A., Aubonne (CH). Oxa-and thiadiazoles and their use as metalloproteinase inhibitors. US2011086893A1; 2011
   Google Scholar
• Brooks PM. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr Opin Rheumatol 2002;14:573-7
   PubMed Web of Science ®Google Scholar
• Baragi VM, Becher G, Bendele AM, et al. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum 2009;60:2008-18
   PubMed Web of Science ®Google Scholar
• Settle S, Vickery L, Nemirovskiy O, et al. Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis: confirmation by multivariate analysis that modulation of type II collagen and aggrecan degradation peptides parallels pathologic changes. Arthritis Rheum 2010;62:3006-15
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories. Isoxazolines as therapeutic agents. WO2012151158A1; 2012
   Google Scholar
• Ranbaxy Laboratories Ltd. Matrix metalloproteinase inhibitors. WO2012038943A1; 2012
   Google Scholar
• Ranbaxy Laboratories Ltd. Matrix metalloproteinase inhibitors. WO2012038942A1; 2012
   Google Scholar
• Ranbaxy Laboratories Ltd. Matrix metalloproteinase inhibitors. WO2012038944A1; 2012
   Google Scholar
• Ranbaxy Laboratories Ltd. Matrix metalloproteinase inhibitors. WO2012014114A1; 2012
   Google Scholar
• Ranbaxy Laboratories Ltd. Matrix metalloproteinase inhibitors. TW201336829A; 2013
   Google Scholar
• Ranbaxy Laboratories Ltd. Matrix metalloproteinase inhibitors. AU2013200728A1; 2013
   Google Scholar
• Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 1990;87:5578-82
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutica Nv, BE. Methods of treatment using allosteric processing inhibitors for matrix metalloproteinases. WO2013003360; 2013
   Google Scholar
• Westfälische Wilhelms-Universität Münster 48149 Münster (DE), Siemens Medical Solutions USA, Inc. Malvern, PA 19355 (US). Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof. EP2644601A1; 2011
   Google Scholar
• Mallinckrodt, Inc. MMP-targeted therapeutic and/or diagnostic nanocarriers. WO2013082389A1; 2013
   Google Scholar
• Universitaet Muenster. Compounds with matrix-metalloproteinase inhibitory activity. WO2013010573A1; 2013
   Google Scholar
• Cordeiro MF. Beyond Mitomycin: TGF-beta and wound healing. Prog Retin Eye Res 2002;21:75-89
   PubMed Web of Science ®Google Scholar
• Wormstone IM. Posterior capsule opacification: a cell biological perspective. Exp Eye Res 2002;74:337-47
   PubMed Web of Science ®Google Scholar
• Di Girolamo N, Chui J, Coroneo MT, et al. Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases. Prog Retin Eye Res 2004;23:195-228
   PubMed Web of Science ®Google Scholar
• University of East Anglia (GB). Treatment of fibrotic eye disorders using an MMP2 inhibitor. US2011236395A1; 2011
   Google Scholar
• Conatus Pharmaceuticals, Inc. Combination therapy for the treatment of liver diseases. US2011212056A1; 2011
   Google Scholar
• Cauwe B, Opdenakker G. Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol 2010;45:351-423
   PubMed Web of Science ®Google Scholar
• Pirard B. Insight into the structural determinants for selective inhibition of matrix metalloproteinases. Drug Discov Today 2007;12:640-6
   PubMed Web of Science ®Google Scholar
• Krzeski P, Buckland-Wright C, Bálint G, et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther 2007;9:R109
   PubMed Web of Science ®Google Scholar